Prednisone
Hormone-Resistant Prostate Carcinoma
Explore 3 assets in Hormone-Resistant Prostate Carcinoma →Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
University of California, Davis
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01949337CT.gov Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer | — | Unknown | — | — | — |
NCT01848067CT.gov Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01685125CT.gov Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | — | Unknown | — | — | — |
NCT01469338CT.gov Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel | — | Terminated | — | — | — |
NCT01468532CT.gov Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01145508CT.gov Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | — | Terminated | — | — | — |
NCT00541281CT.gov Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hormone-Resistant Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Prednisone (this asset) | University of California, Davis | P3 | BB · 70 |
| Abiraterone | Alliance for Clinical Trials in Oncology | P3 | BB |
| Docetaxel | Seattle Institute for Biomedical and Clinical Research | P3 | BB |
| Enzalutamide | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | P3 | BB |
| Bicalutamide | Mayo Clinic | P2 | B |
| Pembrolizumab | University of Wisconsin, Madison | P2 | B |
| Sipuleucel-T | Roswell Park Cancer Institute | P2 | B |
| Saracatinib | National Cancer Institute (NCI) | P2 | B |
| Ipilimumab | OHSU Knight Cancer Institute | P2 | B |
+41 more in the Hormone-Resistant Prostate Carcinoma cohort
Other indications for Prednisone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 74 |
| Diffuse Large B-Cell Lymphoma | — | P4 | BBB · 74 |
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Prednisone in Hormone-Resistant Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/prednisone-hormone-resistant-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →